Cargando…

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells

Acquired T-cell dysfunction is characteristic of chronic lymphocytic leukemia (CLL) and is associated with reduced efficacy of T cell–based therapies. A recently described feature of dysfunctional CLL-derived CD8 T cells is reduced metabolic plasticity. To what extend CD4 T cells are affected and wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Bruggen, J. A. C., van der Windt, G. J. W., Hoogendoorn, M., Dubois, J., Kater, Arnon P., Peters, F. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327552/ https://www.ncbi.nlm.nih.gov/pubmed/35580333 http://dx.doi.org/10.1182/bloodadvances.2022007034

Ejemplares similares

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells
por: Teh, Charis E., et al.
Publicado: (2022)

When CLL meets COVID-19
por: Montserrat, Emili
Publicado: (2020)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
por: Jain, Nitin, et al.
Publicado: (2022)

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022)

Outcomes of COVID-19 in patients with CLL: a multicenter international experience
por: Mato, Anthony R., et al.
Publicado: (2020)

Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021)

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
por: Dickinson, Michael, et al.
Publicado: (2021)

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial
por: Daver, Naval G., et al.
Publicado: (2023)

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
por: Moreno, Carol, et al.
Publicado: (2023)

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
por: Niemann, Carsten U., et al.
Publicado: (2022)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
por: Haselager, Marco V., et al.
Publicado: (2023)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Unrelated donor α/β T cell– and B cell–depleted HSCT for the treatment of pediatric acute leukemia
por: Leahy, Allison Barz, et al.
Publicado: (2022)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
por: Stathis, Anastasios, et al.
Publicado: (2022)

TCRαβ/CD19 depleted HSCT from an HLA-haploidentical relative to treat children with different nonmalignant disorders
por: Merli, Pietro, et al.
Publicado: (2022)

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
por: Michallet, Anne-Sophie, et al.
Publicado: (2023)

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
por: Roddie, Claire, et al.
Publicado: (2023)

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
por: Herishanu, Yair, et al.
Publicado: (2022)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
por: Voorhees, Timothy J., et al.
Publicado: (2022)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
por: van Doesum, Jaap A., et al.
Publicado: (2023)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Tracking the progeny of adoptively transferred virus-specific T cells in patients posttransplant using TCR sequencing
por: Huisman, W., et al.
Publicado: (2022)

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
por: Haggenburg, Sabine, et al.
Publicado: (2022)

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
por: Bader, Peter, et al.
Publicado: (2023)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
por: Karbhari, Nishika, et al.
Publicado: (2022)

Functional Differences Between EBV- and CMV-Specific CD8(+) T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL
por: Hofland, Tom, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1jcb064pj8mun65pv89mef1379